Rovia Clinical Research Launches as Parent Company to East Coast Institute for Research, Universal Axon Clinical Research, and IMIC Inc. Clinical Research Center

JACKSONVILLE, Fla., Sept. 26, 2024 /PRNewswire/ — Rovia Clinical Research is excited to announce the creation of its clinical research site network, which currently includes East Coast Institute for Research (ECIR), Universal Axon Clinical Research (UACR), and IMIC, Inc. Clinical Research Center (IMIC.)

Rovia is at the forefront of advancements across a range of therapeutic areas.

Rovia Clinical Research is a US-based multi-specialty clinical research site network that partners with healthcare providers, pharmaceutical, biotech, and contract research organizations worldwide to facilitate clinical trial delivery. The company’s quality-focused integrated research services for new drugs, devices, and diagnostic studies are designed to offer improved access and new hope to patients from diverse communities.  

With 12 site locations currently in its network, Rovia aims to rapidly expand to become a national site network with locations across the United States. Under the Rovia umbrella, the company will continue to provide central services to the sites within the network.

As Rovia, the combined entities will continue to work closely and collaboratively with sponsors, contract research organizations (CROs), and investigators to ensure that its studies provide unerringly precise results supported by careful data collection and comprehensive analysis. 

Rovia’s capabilities range across therapeutic disciplines, quickly expanding in areas such as Ophthalmology, Metabolism, Cardiovascular, Podiatry, Endocrinology, Gastroenterology, CNS, Hepatology, Infectious Disease, and Urology.

About Rovia Clinical Research
Rovia Clinical Research is dedicated to transforming research methodologies and patient care. As a parent company to multiple research sites, Rovia leverages its extensive network to implement innovative approaches in trial management, data analysis, and patient engagement. Committed to scientific excellence and operational efficiency, Rovia is at the forefront of advancements across a range of therapeutic areas. By fostering collaboration among diverse healthcare stakeholders and prioritizing access for underserved communities, Rovia is not just conducting clinical trials—it is shaping the future of medical research and drug development. Learn More

About Gauge Capital
Gauge Capital is a middle-market private equity firm based in Southlake, Texas. Gauge invests in five key sectors: business services, food & consumer, government & industrial services, healthcare, and technology. The Firm manages more than $3.0 billion in capital. For more information, please contact Chris Garvin, Principal, Business Development at cgarvin@gaugecapital.com.

Contact
PR for Rovia Clinical Research
PR@RoviaClinical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rovia-clinical-research-launches-as-parent-company-to-east-coast-institute-for-research-universal-axon-clinical-research-and-imic-inc-clinical-research-center-302259859.html

SOURCE Rovia Clinical Research

Staff

Recent Posts

Introducing Compassion Center Austin: Pioneering Natural Wellness Solutions Through the Texas Compassionate Use Program (TCUP)

Compassion Center Austin introduces Texans to natural pain management and opioid risk reduction through the…

2 hours ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic painMIAMI, FL /…

2 hours ago

Burning Rock Announces Changes to Management and Board of Directors

GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the…

2 hours ago

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the…

2 hours ago

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS”…

2 hours ago